Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
29/05/2024 13:10
May 29 (Reuters) - Kiromic Biopharma Inc KRBP.PK :
* KIROMIC BIOPHARMA REPORTS FAVORABLE RESULTS AT SIX WEEKS
FROM
FOURTH PATIENT IN DELTACEL-01 CLINICAL TRIAL
* KIROMIC: SCANS OF THIS FIRST PATIENT IN SECOND COHORT SHOW
8.5%
REDUCTION IN TUMOR SIZE
* KIROMIC: TO REPORT PRELIM RESULTS FROM REMAINDER OF
THREE-PATIENT SECOND COHORT IN JUNE
Source text for Eikon: ID:nBw4fcT4Pa
Further company coverage: KRBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site